Autoimmune Biliary Diseases Central

Recent advancements have been made in the treatment of primary biliary cholangitis, particularly for patients who do not respond adequately to first-line treatment.

The long-stagnant primary biliary cholangitis drug market has seen renewed attention in the past 3 months with the addition of two FDA-approved therapy options as well as a costly ruling from an FDA advisory committee.

When Tiffany McLellan was 18 years old, she was diagnosed with an ulcer in her digestive tract. She found relief with antacids for almost 2 years, but after her son was born, she started experiencing digestive issues and pain again.

With the FDA label for Rezdiffra excluding the need for liver biopsy, experts proposed recommendations to “fill the gap” on how to leverage noninvasive tests to assess treatment response in metabolic dysfunction-associated steatohepatitis.

Interim analyses of two phase 2b studies of volixibat support its use as potential treatment for patients with primary biliary cholangitis and primary sclerosing cholangitis, according to a press release from Mirum Pharmaceuticals.

Researchers identified bile duct dysplasia or cancer in most explanted livers with an indication of biliary dysplasia, although as many as 41% had no signs of neoplasia, according to a study of patients with primary sclerosing cholangitis.

In this exclusive Healio interview, Gideon Hirschfield, PhD, MB Bchir, the Lily and Terry Horner Chair in Autoimmune Liver Disease at the University of Toronto, discusses the latest insights into the gut microbiome’s role as a key player in disease development and progression.

A “significantly greater” percentage of patients with primary biliary cholangitis achieved biochemical response, alkaline phosphatase normalization and reduction in pruritis when treated with seladelpar vs. placebo, according to a study.

Didn’t make it to the meeting? Here’s a collection of Healio-curated highlights, including expert insight on the latest research and treatments for biliary diseases, including primary biliary cholangitis, progressive familial cholestasis and more.

Primary biliary cholangitis poses a significant challenge in hepatology, necessitating effective treatment strategies to improve patient outcomes and quality of life.